title: Nitric oxide protection against adriamycin-induced tubulointerstitial injury.
abstract: It is well known that oxidative stress is related to the pathogenesis of adriamycin (ADR) nephropathy. However, it is unclear how nitric oxide (NO) is associated with the pathophysiological process after ADR administration. The NO level in a kidney homogenate was assayed by electron paramagnetic resonance (EPR) spectrometry using a direct in vivo NO trapping technique after ADR administration. N-(3-(aminomethyl)benzyl)acetamidine (1400W) was used as a specific, inducible nitric oxide synthase (iNOS) inhibitor. The levels of NO after ADR administration gradually increased for 6 h and then decreased until 24 h after ADR administration. The fractional excretion of Na (FE(Na)) in the urine was elevated in the ADR group on day 1. Pre-treatment of the animals with 1400W attenuated the increase in NO levels despite further elevation of FE(Na). These findings suggest that iNOS-derived NO does not produce a harmful effect but rather protects the ADR-treated kidney against sodium excretion.
authors.affiliation: International University of Health and Welfare, Nasushiobara, Tochigi, Japan. oteki@iuhw.ac.jp
authors.forename: Takaaki
authors.initials: T
authors.lastname: Oteki
authors.forename: Sohji
authors.initials: S
authors.lastname: Nagase
authors.forename: Homare
authors.initials: H
authors.lastname: Shimohata
authors.forename: Aki
authors.initials: A
authors.lastname: Hirayama
authors.forename: Atsushi
authors.initials: A
authors.lastname: Ueda
authors.forename: Hidekatsu
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Tetsuhiko
authors.initials: T
authors.lastname: Yoshimura
mesh_terms: D000080242:8-Hydroxy-2'-Deoxyguanosine; D000578:Amidines / Q000494:pharmacology; D000818:Animals; D001596:Benzylamines / Q000494:pharmacology; D003849:Deoxyguanosine / Q000031:analogs & derivatives / Q000652:urine; D004317:Doxorubicin; D004578:Electron Spin Resonance Spectroscopy; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007668:Kidney / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009395:Nephritis, Interstitial / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D009566:Nitrates / Q000652:urine; D009569:Nitric Oxide / Q000378:metabolism* / Q000652:urine; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors / Q000378:metabolism; D009573:Nitrites / Q000652:urine; D051381:Rats; D001619:beta-N-Acetylhexosaminidases / Q000652:urine
chemical_list: D000578:Amidines; D001596:Benzylamines; D004791:Enzyme Inhibitors; C104820:N-(3-(aminomethyl)benzyl)acetamidine; D009566:Nitrates; D009573:Nitrites; D009569:Nitric Oxide; D004317:Doxorubicin; D000080242:8-Hydroxy-2'-Deoxyguanosine; D052247:Nitric Oxide Synthase Type II; D001619:beta-N-Acetylhexosaminidases; D003849:Deoxyguanosine